ArticleEClinicalMedicine2021

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.

Linong Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.